Table 1. Patient characteristics.
| |
|
Training cohort (N=258) |
Confirmatory cohort (N=433) |
P-value |
|---|---|---|---|---|
| Variable | Cut point | # (%) | # (%) | |
| Age | <65 years | 123 (47.7) | 199 (46.0) | 0.662 |
| |
⩾65 years |
135 (52.3) |
234 (54.0) |
|
| Sex | Female | 129 (50.0) | 140 (32.3) | <0.001 |
| |
Male |
129 (50.0) |
293 (67.7) |
|
| Stage | III | 69 (26.7) | 65 (15.0) | <0.001 |
| |
IV |
189 (73.3) |
368 (85.0) |
|
| Performance status (ECOG) | 0–1 | 213 (82.6) | 343 (79.2) | 0.284 |
| |
2 |
45 (17.4) |
90 (20.8) |
|
| Smoking status | Never | 39 (15.1) | 65a (15.1) | 0.990 |
| |
Ever |
219 (84.9) |
366a (84.9) |
|
| Weight loss in the preceding 6 months | <5% | 162 (62.8) | 175b (51.3) | 0.005 |
| |
⩾5% |
96 (37.2) |
166b (48.7) |
|
| Chemotherapyc | Double | 197 (76.4) | 293d (68.3) | 0.024 |
| |
Single |
61 (23.6) |
136d (31.7) |
|
| Pathology (NSCLC) | Adenocarcinoma | 166 (64.3) | 300 (69.3) | 0.180 |
| |
Other |
92 (35.7) |
133 (30.7) |
|
| C-reactive protein | ⩽10 mg l–1 | 107 (41.5) | 264 (61.0) | <0.001 |
| |
>10 mg l–1 |
151 (58.5) |
169 (39.0) |
|
| Albumin | >38 g l–1 | 178 (69.0) | 245 (56.6) | 0.001 |
| |
⩽38 g l–1 |
80 (31.0) |
188 (43.4) |
|
| Lactate dehydrogenase | ⩽250 U l–1 | 183 (70.9) | 282 (65.1) | 0.116 |
| |
>250 U l–1 |
75 (29.1) |
151 (34.9) |
|
| Absolute neutrophil count/lymphocytes | ⩽4.5 | 150 (58.1) | 219 (50.6) | 0.054 |
| >4.5 | 108 (41.9) | 214 (49.4) |
Abbreviations: ECOG=Eastern Cooperative Oncology Group; NSCLC=non-small cell lung cancer.
a
N=431.
b
N=341.
c
All include platinum-based chemotherapy.
d
N=429.